Korean corporate executives purchased significant stakes in their own companies during the week of July 28 to August 4, 2026, with five cases exceeding 1 billion won each, according to disclosures from Korea's Financial Supervisory Service. The purchases occurred during a period of market corrections, with July 2026 recording 13 such transactions—the highest monthly count this year. Executives including Kim Yong-joo of Ligachem Biosciences (1.524 billion won), Kim Jong-hee of Dongsuh (11.848 billion won), and Chey Tae-won of SK Hynix (4.900 billion won) acquired shares after their companies' stocks declined, with SK Hynix falling 27.89% and Ligachem Biosciences dropping 23.09% over the prior month. Market analysts interpret these insider purchases as signals that executives believe their companies are undervalued relative to intrinsic business value. The trend marks a shift from previous years when large institutional investor purchases dominated market attention.
Five Executives Purchase Over 1 Billion Won in Own Company Stocks
From July 28 to August 4, 2026, five corporate leaders made individual stock purchases exceeding 1 billion won in their own companies. Kim Yong-joo, chairman of Ligachem Biosciences, purchased 1.524 billion won worth of shares. Kim Young-hoon, CEO of Daesung Venture Capital, acquired 1.038 billion won. Kim Jong-hee, co-CEO of Dongsuh, bought 11.848 billion won. Kwak Dong-shin, chairman of Hanmi Semiconductor, purchased 5.004 billion won. Chey Tae-won, chairman of SK Group, acquired 4.900 billion won in SK Hynix shares. These figures exclude purchases made under institutional or corporate names.
The frequency of such purchases increased throughout 2026. Monthly counts of executives buying 1 billion won or more remained in single digits from January through May (6, 1, 7, 6, and 5 cases respectively). June saw 11 cases, followed by July's peak of 13 cases. By August 4, two additional cases had already been disclosed.
Stock Price Declines Preceded Executive Purchases
Most companies whose executives made recent purchases experienced stock price corrections in the preceding month. Between July 3 and August 4, SK Hynix stock declined 27.89%. Ligachem Biosciences fell 23.09%. Hanmi Semiconductor dropped 7.52%, and Dongsuh decreased 0.59%. Daesung Venture Capital was the sole exception, rising 1.86% during the same period.
Ligachem Biosciences Chairman Cites Platform Competitiveness
Ligachem Biosciences provided an official statement explaining Kim Yong-joo's purchase rationale. A company representative stated: "Chairman Kim Yong-joo's purchase reflects responsible management driven by confidence in the company's accumulated platform competitiveness and the mid-to-long-term value of its pipeline, despite recent stock price declines due to rapid changes in the macro environment. We will continue to enhance shareholder value through multiple clinical achievements and technology transfer results."
Capital Market Institute Researcher Analyzes Insider Buying Signals
Kang So-hyun, a researcher at the Capital Market Institute, explained the significance of executive stock purchases. "Management has more information about a company's real value than external investors," Kang stated. "If an insider purchases company stock under their personal name, it can be interpreted as a stronger signal that the company is undervalued."
Kang distinguished between personal executive purchases and corporate share buybacks. Executive purchases involve personal funds and represent responsible management actions, while corporate buybacks use company funds as shareholder return policies.
Kang noted limitations to using insider purchases as investment signals. "Investors are in a position with less information than internal management due to information asymmetry between insiders and external shareholders," Kang said. "If the judgment that corporate value is undervalued is correct, insiders are likely to continue holding their shares afterward, but if not, the incentive to maintain those shares may not be large."
FAQ
How many Korean executives purchased over 1 billion won of their own company stocks in July 2026?
July 2026 recorded 13 cases of executives purchasing 1 billion won or more of their own company stocks, the highest monthly count in 2026. From July 28 to August 4 alone, five such purchases occurred, including transactions by executives at Ligachem Biosciences, Dongsuh, SK Hynix, Hanmi Semiconductor, and Daesung Venture Capital.
Why did SK Hynix chairman Chey Tae-won purchase company shares in early August 2026?
Chey Tae-won purchased 4.900 billion won worth of SK Hynix shares during the week of July 28 to August 4, 2026, after the stock declined 27.89% between July 3 and August 4. Market analysts interpret such insider purchases as signals that executives believe their companies are undervalued during market corrections.
What did Ligachem Biosciences say about Chairman Kim Yong-joo's stock purchase?
Ligachem Biosciences stated that Kim Yong-joo's 1.524 billion won purchase reflected confidence in the company's platform competitiveness and pipeline value despite stock price declines from macro environment changes. The company described the purchase as a responsible management decision and committed to enhancing shareholder value through clinical and technology transfer achievements.
